The ability to program naïve cells or to reprogram differentiated cells into particular fates will open the door to the discovery of novel therapeutics for diseases such as diabetes. The goal of my lab is to understand the fundamental principles that govern the identity of a cell, and to use these principles to manipulate cell fates for regenerative medicine. In pursuit of this goal, we employ a variety of approaches including cellular programming and reprogramming through gene transduction, directed differentiation of embryonic stem (ES) cells, chemical screening, mouse genetics, adult tissue injury and regeneration, and tissue/cell transplantation.
Danwei Huangfu, PhD
Research FocusDevelopmental biologist Danwei Huangfu investigates the fundamental mechanisms that govern cell identity and how they could be exploited therapeutically to manipulate cell fates in regenerative medicine.
- PhD, Cornell University
- González F, Zhu Z, Shi ZD, Lelli K, Verma N, Li QV, Huangfu D. An iCRISPR Platform for Rapid, Multiplexable, and Inducible Genome Editing in Human Pluripotent Stem Cells. Cell Stem Cell. 2014 Jun 11;S1934-5909(14)00205-7.
- González F, Georgieva D, Vanoli F, Shi ZD, Stadtfeld M, Ludwig T, Jasin M, Huangfu D. Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep. 2013 Mar 28;3(3):651-60. doi: 10.1016/j.celrep.2013.02.
- Basil O’Connor Scholar, March of Dimes Birth Defects Foundation (2012-2014)
- Louis V. Gerstner, Jr. Young Investigators Award, Memorial Sloan Kettering Cancer Center (2011-2014)
- Award from Harvard Catalyst & InnoCentive for the Ideation Challenge on “What Do We Not Know to Cure Type 1 Diabetes” (2010)
- Helen Hay Whitney Postdoctoral Fellowship (2006-2009)